A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor-Hair Serum for the Prevention of Chemotherapy-Induced Alopecia - PubMed
5 hours ago
- #breast cancer
- #keratinocyte growth factor
- #chemotherapy-induced alopecia
- A nonrandomized clinical trial investigated Keratinocyte Growth Factor-Hair Serum (KGF-HS) for preventing chemotherapy-induced alopecia (CIA).
- The study involved 20 women with early-stage breast cancer (ESBC) receiving chemotherapy.
- Primary outcome was hair preservation post-chemotherapy, but none achieved meaningful results.
- Secondary measures included patient-reported wig use, comfort, and quality-of-life assessments (EORTC QLQ-C30, HADS, BIS).
- Average KGF-HS application duration was 4.6 weeks, with no significant hair preservation observed.
- No statistical differences were found in pre- and post-study quality-of-life scores.
- Patients reported KGF-HS as easy to use, with minimal discomfort and non-oily appearance.
- The study supports the need for more practical and affordable alternatives to scalp cooling for CIA prevention.